(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
08 December 2022 (08.12.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/256806 A1

(51) International Patent Classification:
C07D 239/95 (2006.01) *C07D 471/04* (2006.01)
A61K 31/519 (2006.01)

(21) International Application Number:
PCT/US2022/072693

(22) International Filing Date:
01 June 2022 (01.06.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/196,008	02 June 2021 (02.06.2021)	US
63/362,438	04 April 2022 (04.04.2022)	US
63/364,360	09 May 2022 (09.05.2022)	US

(71) Applicant: **IDEAYA BIOSCIENCES, INC.** [US/US]; 7000 Shoreline Court, Suite 350, South San Francisco, California 94080 (US).

(72) Inventors: **DILLON, Michael Patrick**; c/o IDEAYA BIOSCIENCES, INC., 7000 Shoreline Court, Suite 350, South San Francisco, California 94080 (US). **NEILAN, Claire L.**; c/o IDEAYA BIOSCIENCES, INC., 7000 Shoreline Court, Suite 350, South San Francisco, California 94080 (US). **FISCHER, Marcus Michael**; c/o IDEAYA BIOSCIENCES, INC., 7000 Shoreline Court, Suite 350, South San Francisco, California 94080 (US). **GERRICK, Kimberline Yang**; c/o IDEAYA BIOSCIENCES, INC., 7000 Shoreline Court, Suite 350, South San Francisco, California 94080 (US).

(74) Agent: **TRINQUE, Brian C.**; c/o Lathrop GPM LLP, 28 State Street, Boston, Massachusetts 02109 (US).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(54) Title: COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND A TYPE II PRMT INHIBITOR

FIGURE 1



(57) Abstract: Provided herein is a combination product comprising a methionine adenosyltransferase II alpha (MAT2A) inhibitor and a Type II protein arginine methyltransferase (Type II PRMT) inhibitor. The combination product is useful for the treatment of a variety of cancers, including solid tumors. The combination product is useful for the treatment of any number of MAT2A-associated and/or PRMT-associated diseases.

WO 2022/256806 A1